


17224(AP)



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of )

Group Art Unit: 1616

Sefton )

Examiner: B. Badio

Serial No.: 09/367,712 )

Filed: August 18, 1999 )

For: TAZAROTENE AND CORTICO-  
STERIOD TREATMENT FOR  
PSORIASIS )

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Commissioner of Patents and Trademarks,  
Washington, D.C. 20231 on:

Date of Deposit: Oct. 13, 2000

Print Name: Cynthia H. O'Donohue

Signature: C. H. O'Donohue

Date of Signature: Oct. 13, 2000

Box Non Fee Amendment  
Commissioner of Patents and  
Trademarks  
Washington, D.C. 20231

REPLY UNDER 37 CFR § 1.113 AND 37 CFR § 1.116

RECEIVED

OCT 19 2000

TECH CENTER 1600/2000

Sir:

The Office Action of July 21, 2000, which was made final, has been received and  
carefully studied. In response, the applicant has the following amendment and remarks.

AMENDMENT

Please amend the above-identified patent application in the claims as follows:

Claim 5 [twice amended]. The method of claim 2 wherein said corticosteroid is  
selected from the group consisting of mometasone furoate and alclometasone dipropionate

Please see  
3/5/07